Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Growth Rate of the Postmenopausal Osteoporosis Treatment Market?
The market size for treatment of postmenopausal osteoporosis has seen a consistent growth over the recent years. It is projected to expand from $10.1 billion in 2024 to $10.58 billion in 2025, growing at a compound annual growth rate (CAGR) of 4.8%. Factors like an ageing population, usage of hormone replacement therapy, heightened awareness, reduction in risk of fractures, and nutritional supplements have contributed to the growth seen in the historic period.
What Growth Rate Is Forecasted for the Postmenopausal Osteoporosis Treatment Market by 2029?
It is anticipated that the market size of postmenopausal osteoporosis treatment will experience significant growth in the coming years, reaching a value of $13.44 billion in 2029 with a CAGR of 6.2%. This growth over the forecast period can be connected to improvements in healthcare infrastructure, the expansion of screening programs, the use of precision medicine and biosimilars in osteoporosis treatment, focus on bone health in women’s health initiatives, the melding of digital health, and the application of regenerative medicine strategies. Key trends predicted for this period encompass advances in diagnostic techniques, the creation of new drugs, the advent of novel therapies, partnerships to facilitate drug development, and the utilization of artificial intelligence.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12680&type=smp
Which Key Companies Are Shaping the Future of the Postmenopausal Osteoporosis Treatment Market?
Major companies operating in the postmenopausal osteoporosis treatment market include Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche AG, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Eli Lilly and Company, Amgen Inc., Asahi Kasei Corporation, Viatris Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Sandoz International GmbH, Fresenius Kabi AG, Daiichi Sankyo Company Ltd., Sun Pharmaceutical Industries Ltd., Cipla Inc., Dr.Reddys Laboratories Ltd., Hikma Pharmaceuticals PLC., Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Takeda Pharmaceutical Company Limited, Lupin Limited, Ligand Pharmaceuticals Incorporated, Torrent Pharmaceuticals Limited.
Which Factors Are Driving Demand in the Postmenopausal Osteoporosis Treatment Industry?
The rise in osteoporosis occurrences is anticipated to stimulate the expansion of the postmenopausal osteoporosis treatment market in the future. Osteoporosis is a health condition characterised by reduced bone mass and degraded bone tissue, leading to increased vulnerability and fracture risk. Postmenopausal osteoporosis treatment aids in preventing or managing the disease, thereby reducing fracture risks and enhancing the life quality and overall health results for those afflicted. For example, as cited by Healthy Bones Australia, an Australia-based NGO, in September 2022, there was an increase in the number of fractures induced by osteoporosis or osteopenia, from 178,439 in 2021 to 183,105 in 2022. Hence, the escalating prevalence of osteoporosis is fueling the progression of the postmenopausal osteoporosis treatment market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=12680&type=smp
How Is the Postmenopausal Osteoporosis Treatment Market Segmented by Several Divisions?
The postmenopausal osteoporosis treatment market covered in this report is segmented –
1) By Drug Type: Bisphosphonates, Vitamin D3, Estrogen Agonist Or Antagonist, Hormone Replacement Therapy, Parathyroid Hormone Therapy, Other Drug Types
2) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
Subsegments:
1) By Bisphosphonates: Alendronate, Risedronate, Zoledronic Acid
2) By Vitamin D3: Cholecalciferol, Ergocalciferol
3) By Estrogen Agonist Or Antagonist: Selective Estrogen Receptor Modulators (SERMs), Tamoxifen
4) By Hormone Replacement Therapy: Estrogen Therapy, Combined Estrogen-Progestin Therapy
5) By Parathyroid Hormone Therapy: Teriparatide, Abaloparatide
6) By Other Drug Types: Calcitonin, RANK Ligand Inhibitors
What are the Emerging Market Trends Driving the Growth of the Postmenopausal Osteoporosis Treatment Industry?
A primary trend gaining momentum in the postmenopausal osteoporosis treatment market is product innovation. Top-tier companies in the market are centring their attention on the innovation of products such as parathyroid hormone (PTH), aiming to increase its effectiveness and patient compliance. They are investigating combination therapies and personalized medicine to improve results. Moreover, they are putting emphasis on long-term safety research and patient support schemes to alleviate concerns and encourage adherence. PTH is a hormone generated by the parathyroid glands controlling the levels of calcium in the blood. It stimulates the release of calcium from the bones, increases reabsorption in the kidneys, and activates vitamin D to increase calcium absorption in the intestines. An example of this is Apotex Corp., a pharmaceutical firm based in Canada, which launched teriparatide in November 2023. Teriparatide is a synthetically produced PTH that substantially increases bone mineral density and decreases the risks of fractures in osteoporosis patients. Its anabolic effects stimulate bone formation, marking it as a vital treatment for high-risk patients.
Access The Full Report Here:
Which Regions Are Driving Growth in the Postmenopausal Osteoporosis Treatment Market?
North America was the largest region in the postmenopausal osteoporosis treatment market in 2024. The regions covered in the postmenopausal osteoporosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12680
This Report Delivers Insight On:
1. How big is the postmenopausal osteoporosis treatment market, and how is it changing globally?
2. Who are the major companies in the postmenopausal osteoporosis treatment market, and how are they performing?
3. What are the key opportunities and risks in the postmenopausal osteoporosis treatment market right now?
4. Which products or customer segments are growing the most in the postmenopausal osteoporosis treatment market?
5. What factors are helping or slowing down the growth of the postmenopausal osteoporosis treatment market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
